Delving into the Latest Updates on Minghui Pharmaceutical (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Neoplasms

Immune System Diseases

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	2
Small molecule drug	2

Top 5 Target	Count

V-set domain containing	1
IGF-1R(Insulin-like growth factor I receptor)	1
BTK C481S(Bruton Tyrosine Kinase C481S)	1

主要目的：评价 MH048 在复发/难治性 B-NHL 患者中的安全性及耐受性，确定 MH048 的最大耐受剂量（MTD）和推荐Ⅱ期临床剂量（RP2D）次要目的：研究 MH048 及其活性代谢产物 M3 在复发/难治性 B-NHL 患者中的药代动力学特性。获得 MH048 在复发/难治性慢 B-NHL 患者中的抗肿瘤活性的初步数据。

[Translation]

Primary objective: To evaluate the safety and tolerability of MH048 in patients with relapsed/refractory B-NHL, and to determine the maximum tolerated dose (MTD) and recommended phase II clinical dose (RP2D) of MH048. Secondary objective: To study the pharmacokinetic properties of MH048 and its active metabolite M3 in patients with relapsed/refractory B-NHL. To obtain preliminary data on the anti-tumor activity of MH048 in patients with relapsed/refractory chronic B-NHL.

Start Date07 Dec 2021

Sponsor / Collaborator

Minghui Pharmaceutical (Shanghai) Co., Ltd.

CTR20202457

/ RecruitingPhase 1

MH048 用于复发/难治性 B 细胞恶性肿瘤患者的安全性、药代动力学以及抗肿瘤药效的多中心、开放标签、剂量递增及队列扩展 Ⅰ/Ⅱ 期临床研究

[Translation] A multicenter, open-label, dose-escalation and cohort expansion Phase I/II clinical study of the safety, pharmacokinetics and antitumor efficacy of MH048 in patients with relapsed/refractory B-cell malignancies

主要目的：评价 MH048 在复发/难治性 B-NHL 患者中的安全性及耐受性确定 MH048 的最大耐受剂量（MTD），并基于方案定义的剂量限制性毒性次要目的：研究 MH048 及其活性代谢产物 M3 在复发/难治性 B-NHL 患者中的药代动力学特性。获得 MH048 在复发/难治性慢 B-NHL 患者中的抗肿瘤活性的初步数据。

[Translation]

Primary objective: To evaluate the safety and tolerability of MH048 in patients with relapsed/refractory B-NHL. To determine the maximum tolerated dose (MTD) of MH048 and the dose-limiting toxicity defined by the protocol. Secondary objective: To study the pharmacokinetic properties of MH048 and its active metabolite M3 in patients with relapsed/refractory B-NHL. To obtain preliminary data on the anti-tumor activity of MH048 in patients with relapsed/refractory chronic B-NHL.

Start Date07 Jan 2021

Sponsor / Collaborator

Minghui Pharmaceutical (Shanghai) Co., Ltd.

NCT04689308

/ Unknown statusPhase 1

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of MH048 in Subjects With Selected Relapsed/Refractory B-cell Malignancies

This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.

Start Date07 Jan 2021

Sponsor / Collaborator

Minghui Pharmaceutical (Shanghai) Co., Ltd.

100 Clinical Results associated with Minghui Pharmaceutical (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Minghui Pharmaceutical (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with Minghui Pharmaceutical (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Minghui Pharmaceutical (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Phase 2 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MH080	Plaque psoriasis More	Phase 2
MH-048 ( BTK C481S )	B-Cell Malignant Neoplasm More	Phase 2
WO2023143484 ( IGF-1R )	Skin and Connective Tissue Diseases More	Discovery
WO2022161454 ( V-set domain containing )	Neoplasms More	Discovery
Tofacitinib etocomil ( JAK )	Autoimmune Diseases More	Pending